Using levity to battle a serious disease, entertainer Seth Rogen and his wife raised more than $325,000 for HFC, the couple’s national Alzheimer’s disease organization, during its first virtual game show. The funds will help in providing at-home care at no extra charge to Alzheimer’s patients, as well as…
A first patient has been dosed in a Phase 2 trial evaluating the effects of ALZ-801 on disease-related biomarkers in people with early Alzheimer’s disease, who have a specific genetic variant associated with an increased risk of disease progression. “This biomarker study is a key element of our…
A simple language test, when combined with an artificial intelligence model, can predict which people will develop Alzheimer’s disease later in life, a study shows. This new model predicted Alzheimer’s seven years before its diagnosis with an accuracy of 70%, according to the study. That rate is higher…
RetiSpec and Gentex are partnering to develop a technology to detect Alzheimer’s disease — potentially years before symptom onset — using a non-invasive and cost-effective eye scan technique. The partnership between the two companies will expedite the development of the technology, with the goal of bringing it…
A first patient has been dosed in a Phase 2 trial investigating the safety and long-term efficacy of bryostatin-1 in treating moderate and moderately severe Alzheimer’s disease, the therapy’s developer, Neurotrope, announced. The trial (NCT04538066), which is recruiting patients at several sites across the U.S., will build…
GemVax & KAEL has filed for expanded access of its U.S. Food and Drug Administration (FDA) investigational new drug (IND) application for GV1001, its experimental treatment for Alzheimer’s disease. The company is seeking to include additional investigational groups in its clinical development program. The…
Dosing of patients has begun in a Phase 2/3 clinical trial evaluating ATH-1017, Athira Pharma‘s investigational candidate for the treatment of mild to moderate Alzheimer’s disease. “Embarking on this trial to evaluate our new approach to treating Alzheimer’s is the start of a collective experience that will involve…
Note: This story was updated Oct. 12, 2020, to note that semorinemab is intended to target phosphorylated and non-phosphorylated forms of tau. Semorinemab, a monoclonal antibody against tau, failed to significantly alter dementia’s progression in people with early Alzheimer’s disease (AD) taking part in a Phase 2 clinical…
The National Institute on Aging, a division of the National Institutes of Health, is awarding a $1.76 million, one-year grant to support a Phase 1 clinical trial investigating oral Jotrol as a potential treatment of early stage Alzheimer’s disease. The study is to be called “Safety and Pharmacokinetics…
The Alzheimer’s Association has been chosen to lead a national public health effort aimed at lowering the risk of cognitive decline and dementia. The organization was selected by the Centers for Disease Control and Prevention (CDC) as a Building Our Largest Dementia (BOLD) Public Health Center…
Get regular updates to your inbox.